EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy.

Uhlyarik, Andrea; Piurko, Violetta; Papai, Zsuzsanna; Raso, Erzsebet; Lahm, Erika; Kiss, Edina; Sikter, Marta; Vachaja, Jozsef; Kenessey, Istvan; Timar, Jozsef

Uhlyarik, Andrea; Piurko, Violetta; Papai, Zsuzsanna; Raso, Erzsebet; Lahm, Erika; Kiss, Edina; Sikter, Marta; Vachaja, Jozsef; Kenessey, Istvan; Timar, Jozsef.

Afiliación

Uhlyarik A; Department of Oncology, Medical Center, Hungarian Defence Forces, 1065 Budapest, Hungary.
Piurko V; 2nd Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
Papai Z; Department of Oncology, Medical Center, Hungarian Defence Forces, 1065 Budapest, Hungary.
Raso E; 2nd Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
Lahm E; Department of Oncology, Medical Center, Hungarian Defence Forces, 1065 Budapest, Hungary.
Kiss E; Department of Oncology, Medical Center, Hungarian Defence Forces, 1065 Budapest, Hungary.
Sikter M; Department of Oncology, Medical Center, Hungarian Defence Forces, 1065 Budapest, Hungary.
Vachaja J; Department of Oncology, Medical Center, Hungarian Defence Forces, 1065 Budapest, Hungary.
Kenessey I; 2nd Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
Timar J; 2nd Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.

Cancers (Basel) ; 12(3)2020 Mar 06.

Article en En | MEDLINE | ID: mdl-32155907

Palabras clave

Cetuximab; EGFR protein; metastatic colorectal cancer; survival

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google